生物技术公司Abivax盘前涨10.5%，传礼来可能有意收购该公司

Core Viewpoint - The French biotechnology company Abivax (ABVX.US) saw a pre-market increase of 10.5%, reaching $135.97, amid speculation that Eli Lilly may be interested in acquiring the company. Eli Lilly has stated that it does not comment on business development activities [1] Group 1: Company Performance - Abivax reported positive results from a Phase III clinical trial of obefazimod for the treatment of ulcerative colitis in July [1]